FDA Rejects Eagle Pharmaceuticals ' Heat Stroke Treatment FDA Rejects Eagle Pharmaceuticals ' Heat Stroke Treatment
Eagle Pharmaceuticals Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its drug Ryanodex (dantrolene sodium) to treat heat stroke and requested an additional clinical trial, sending its shares down 20 percent.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Family Medicine/Primary Care News Source Type: news
More News: Clinical Trials | Food and Drug Administration (FDA) | Health | Heatstroke | Primary Care | Sodium | Stroke